Keywords: erbitux, almost, double, kras, response, trial, merck

Erbitux has almost double KRAS response in trial

Article | 12 January 2009

Print This

Merck Serono, the pharmaceutical arm of Germany's Merck KGaA, has published the results of a study, demonstrating that the addition ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in